Skip to main content

Elena Vargas Accarino

Institutions of which they are part

Postdoctoral researcher
Liver Diseases
Vall Hebron Institut de Recerca

Elena Vargas Accarino

Institutions of which they are part

Postdoctoral researcher
Liver Diseases
Vall Hebron Institut de Recerca

Projects

Malalties hepàtiques

IP: Joan Genescà Ferrer
Collaborators: Beatriz Minguez Rosique, Sergi Colomer Castell, Elena Vargas Accarino, Immaculada Raurell Saborit, Lluís Viladomiu Catà, Lluis Castells Fusté, Maria del Mar Riveiro Barciela, Victor Manuel Vargas Blasco, Maria Buti Ferret, Montserrat Gomez Perez, Torrens Buscató, Maria Margarita, Judit Vico Romero, Josep Quer Sivila, Adriana Palom Agusti, Juan Manuel Pericàs Pulido, Maria Nieves Martell Pérez-Alcalde, Damir Garcia Cehic, Daniel Martinez Vazquez, Laura Puente Ramo, Isabel Campos Varela, María Bermúdez Ramos, Juan Ignacio Esteban Mur, Ester Palacio Gutierrez, Susana Anton Calvo, Monica Higuera Urbano, Elena de Sena Fernández, Meritxell Ventura Cots, Ares Aurora Villagrasa Vilella, Emma Bigas Alsina, Carolina Campos Martinez, Macarena Simon-Talero Horga, Jesus Manuel Rivera Esteban, David Tabernero Caellas, Mònica Pons Delgado, Marcella Salzano, Cesar Jimenez Hernandez
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 60000
Reference: 2021 SGR 00462
Duration: 01/01/2022 - 31/12/2024

Aislamiento y caracterización molecular de Células Tumorales Circulantes (CTCs): potenciales biomarcadores en Carcinoma Hepatocelular

IP: Beatriz Minguez Rosique
Collaborators: Itxarone Izaskun Bilbao Aguirre, Elena Vargas Accarino, Torrens Buscató, Maria Margarita, Maria Teresa Salcedo Allende, Monica Higuera Urbano
Funding agency: Instituto de Salud Carlos III
Funding: 183920
Reference: PI21/00714
Duration: 01/01/2022 - 31/12/2024

Desarrollo de un test rápido de diagnóstico precoz de hepatocarcinoma en biopsia líquida, usando PCR en tiempo real y secuenciación masiva.

IP: Maria Buti Ferret
Collaborators: Elena Vargas Accarino, Laia Perez Lasarte
Funding agency: Instituto de Salud Carlos III
Funding: 82400
Reference: FI18/00027
Duration: 01/01/2019 - 13/04/2023

Related news

Preliminary study results confirm that the drug resmetirom reduces the presence of fat, inflammation, cell damage and fibrosis in the liver.

The European project, in which Vall d'Hebron participates, will favor personalized diagnosis and innovative therapeutic strategies in patients with the disease.

The research team used nanotechnology to deliver the drug directly to liver cells, which eliminated side effects without reducing effectiveness.

Related professionals

Victor Franco Puntes

Victor Franco Puntes

Head of group
Pharmacokinetic Nanoparticles
Read more
Carolina Ramos Sayalero

Carolina Ramos Sayalero

Research technician
Psychiatry, Mental Health and Addictions
Read more
Anna Santamaria Margalef

Anna Santamaria Margalef

Director/a d'Àrea
Teaching Area
Read more
Luis Ignacio Soto Bargaria

Luis Ignacio Soto Bargaria

Predoctoral researcher
Research on Aging, Frailty and Transitions in Barcelona
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.